Thursday, April 3, 2025 4/3/2025

Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention

Award Number: R37CA263064
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention - There is strong evidence that cancer treatment contributes to increased comorbidity, functional decline, and accelerated biologic aging. Resistance training (RT) interventions may help to minimize this functional decline by increasing lean mass. Patients diagnosed with colon cancer are particularly likely to benefit from RT interventions given the high prevalence of involuntary loss of skeletal muscle mass (sarcopenia) at diagnosis, which is associated with chemotherapy- associated toxicities, and poor prognosis. Epigenetic clocks, which predict chronologic or phenotypic age based on specific patterns of DNA methylation (DNAm), are easy to assay, well- validated markers of biologic aging. Those with higher epigenetic age acceleration (AgeAccel; DNAm-estimated age adjusting for chronologic age) are at an elevated risk for morbidity (early onset of functional impairment, frailty and other aging syndromes) and mortality, independent of other predictors of longevity. We hypothesize that colon cancer patients with higher blood AgeAccel will be at greater risk for chemotherapy toxicities, dose reductions, and delays, that AgeAccel will increase during colon cancer chemotherapy, and that a RT intervention can reduce the rate of epigenetic aging. We further hypothesize that AgeAccel measured in blood and tumor tissue will be related to colorectal cancer molecular subtypes and patient prognosis. We plan to investigate these hypotheses in collaboration with the Resistance Training to Reduce Chemotoxicity in Colon Cancer (FORCE) clinical trial. This clinical trial of RT in stage II and III colon cancer patients includes detailed treatment and participant information, tumor specimens, longitudinal collection of blood and multimodal measures of body composition. Our aims will investigate whether several measures of blood AgeAccel at baseline relate to the incidence of moderate/severe chemotoxicities, and relative dose intensity. We will assess the rate of blood epigenetic aging over chemotherapy, and whether this rate is modified by RT. We will evaluate whether AgeAccel estimated in blood and tumor tissue differs by colorectal cancer molecular subtypes and associations with overall survival, recurrence, comorbidity accumulation, and trajectories of muscle mass. Together, these analyses will provide novel insight into the biologic processes of aging that predict tolerance for cancer treatment and patient prognosis to inform appraisal of whether AgeAccel may serve as a useful tool to guide clinical care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Cancer Cause and Prevention Research	001	4	3/18/2025	EXTENSION WITH OR WITHOUT FUNDS	$373,013
2025	2023	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Cancer Cause and Prevention Research	000	3	3/18/2025	NON-COMPETING CONTINUATION	-$373,013
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $632,572 )
2024	2024	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Cancer Cause and Prevention Research	000	4	8/14/2024	EXTENSION WITH OR WITHOUT FUNDS	$632,572
														Subtotal = $632,572

Issue Date FY: 2023 ( Subtotal = $636,830 )
2023	2023	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Cancer Cause and Prevention Research	001	3	8/23/2023	NON-COMPETING CONTINUATION	$636,830
2023	2022	UNIVERSITY OF HAWAII SYSTEMS	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Cancer Cause and Prevention Research	000	2	2/14/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $636,830

Issue Date FY: 2022 ( Subtotal = $645,794 )
2022	2022	UNIVERSITY OF HAWAII SYSTEMS	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Cancer Cause and Prevention Research	000	2	8/16/2022	NON-COMPETING CONTINUATION	$645,794
														Subtotal = $645,794

Issue Date FY: 2021 ( Subtotal = $549,396 )
2021	2021	UNIVERSITY OF HAWAII SYSTEMS	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Cancer Cause and Prevention Research	000	1	9/8/2021	NEW	$549,396
														Subtotal = $549,396

Grand Total All Awards = $2,464,592

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention

Award Number: R37CA263064

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer